Preparation and Characterization of Albumin Nanoparticles of Paclitaxel-Triphenylphosphonium Conjugates: New Approach to Subcellular Targeting

Abstract

Mitochondria have been recognized as important targets in cancer therapy due to their role in the respiratory process of cells. One approach employed for mitochondrion targeting is conjugation of a delocalized cation such as triphenylphosphonium (TPP), with antineoplastic agents, for instance paclitaxel (PTX). In cell cytoplasm, TPP-PTX can come close to mitochondria due to its high positive charge, which has a strong tendency toward the enhanced negative charge of mitochondria. The esteric bond of TPP-PTX can break down in the acidic environment of tumor cells and release the PTX, which can act directly on mitochondria to kill tumor cells. TPP-PTX was synthesized in three steps: Succinic anhydride (SUC) reacted with PTX to achieve succinyl paclitaxel (SUC-PTX), which has an acid-labile esteric bond. Then 2-triphenylphosphonium ethylammonium (ATPP) was prepared by attaching 2-bromoethylammunium bromide to TPP. Finally, a TPP-PTX prodrug was synthesized by attaching these materials. The products of all steps were characterized by thin-layer chromatography (TLC), infrared spectroscopy (IR), and nuclear magnetic resonance (¹H NMR, ¹³C NMR). The purity of the products was determined by HPLC methods. TPP-PTX, as a prodrug, was loaded in to human serum albumin (HSA) nanoparticles by a method inspired by nab-technology with 130–160 nm particle size distribution, PdI=0.166 and Zeta potential −12.6 mV.

Key words

paclitaxel - triphenylphosphonium - human serum albumin - EPR effect - targeted delivery - nanoparticles

• References

• 1 Priyadarshini K, Keerthi Aparajitha U. Paclitaxel against cancer: A short review. Med Chem 2012; 2: 139-141
• 2 Andre N, Carre M, Brasseur G. et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS 2002; 532: 256-260
• 3 Andre N, Braguer D, Brasseur G. et al. Paclitaxel Induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000; 60: 5349-5353
• 4 Scatena R. Mitochondria and cancer: A growing role in apoptosis, cancer cell metabolism and dedifferentiation. Medicine and Biology 2012; 942: 287-308
• 5 Zhou J, Zhao WY, Ma X. et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 2013; 34: 3626-3638
• 6 Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004; 7: 97-110
• 7 Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: What is so special about them?. Trends Cell Biol 2008; 18: 165-173
• 8 D'Souza GGM, Wagle MA, Saxena V. et al. Approaches for targeting mitochondria in cancer therapy. BBA 1807(6) 2011; 689-696
• 9 Reily C, Mitchell T, Chacko BK. et al. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol 2013; 1: 86-93
• 10 Ross MF, Ros TD, Blaikie FH. et al. Accumulation of lipophilic dications by mitochondria and cells. Biochem J 2006; 400: 199-208
• 11 Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012; 157: 168-182
• 12 Zhao D, Zhao X, Zu Y. et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine 2010; 5: 669-677
• 13 Iyer AK, Khaled G, Fang J. et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today11(17/18) 2006; 812-818
• 14 Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010; 148: 135-146
• 15 Elsadek B, Kratz F. Impact of albumin on drug delivery — New applications on the horizon. J Control Release 2012; 157: 4-28
• 16 Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132: 171-183
• 17 Desai N. Nab Technology: A drug delivery platform utilising endothelial' gp60 receptor-based transport and tumourderived SPARC for targeting. Drug Deliv 2008; 35-41
• 18 Nateghian N, Goodarzi N, Amini M. et al. Biotin/Folate-decorated human serum albumin nanoparticles of docetaxel: Comparison of chemically conjugated nanostructures and physically loaded nanoparticles for targeting of breast cancer. Chem Biol Drug Des 2015; 87: 1-14
• 19 Services, U.S.D.o.H.a.H.e.a (1996) Validation of Analytical Procedures: Methodology. ICH Topic Q2B step 4: CPMP/ICH/281/95
• 20 Services, U.S.D.o.H.a.H.e.a (1995) Validation of Analytical Methods: Definitions and Terminology. ICH Topic Q2A step 5: CPMP/ICH/381/95
• 21 Hosseinifar N, Amini M, Goodarzi N. et al. Preparation of Human Serum Albumin Nanoparticles Using a Chemometric Technique. JNSC 2017; 7: 327-335
• 22 Dosio F, Brusa P, Crosasso P. et al. Preparation, characterization and properties in vitro and in vivo of a paclitaxel–albumin conjugate. J Control Release 1997; 47: 293-304
• 23 Esmaeili F, Dinarvand R, Ghahramani MH. et al. Docetaxel–albumin conjugates: Preparation, in vitro evaluation and biodistribution studies. J Pharm Sci 2009; 98: 2718-2730
• 24 Goodarzi N, Ghahremani MH, Amini M. et al. CD44-targeted docetaxel conjugate for cancer cells and cancer stem-like cells: A novel hyaluronic acid-based drug delivery system. Chem Biol Drug Des 2014; 83: 1-12
• 25 Finichiu PG, James AM, Larsen L. et al. Mitochondrial accumulation of a lipophilic cation conjugated to an ionisable group depends on membrane potential, pH gradient and pKa: Implications for the design of mitochondrial probes and therapies. J Bioenerg Biomembr 2013; 45: 165-173
• 26 Pavia DL. et al Introduction to Spectroscopy. 5th Edition. USA: Cengage Learning, 2013; 318